Scholarlink

Purpose <p>This study aims to characterize treatment patterns for chronic lymphocytic leukemia (CLL) in real-world clinical practice across Greece focusing on both treatment-naïve and relapsed or refractory (R/R) disease. We evaluated therapeutic patterns and outcomes [including overall survival (OS), time to next treatment or death (TTNT-D) and overall response rate (ORR)] and documented the incidence of other malignancies of patients who initiated first-line treatment between 2010 and 2024.</p> Methods <p>This is a panhellenic multicenter retrospective study of patients diagnosed with CLL between 2010 and 2020 from 8 centers in Greece.</p> Results <p>Overall, 1318 patients were included in the study. Fludarabine, cyclophosphamide and rituximab (FCR) was the most common first-line regimen (21.6%), followed by chlorambucil plus rituximab (16.3%) and ibrutinib-based therapies (14%). In the R/R setting, ibrutinib and venetoclax-based treatments, became the predominant therapeutic choices after 2014, replacing chemoimmunotherapy. Shifts in treatment patterns before and after 2016 reflected the incorporation of targeted agents into routine clinical practice, with a marked decline in FCR use and increased adoption of targeted therapies. Median OS was 162&#xa0;months from diagnosis and 105.2&#xa0;months (95% CI: 90.3–116.3) from first treatment. In patients receiving ibrutinib as first-line therapy, mOS was not reached, and median TTNT-D was 67.3&#xa0;months.</p> <p>Overall, 18 (1.4%) cases developed a second hematological malignancy and 59 (4.5%) were diagnosed with a solid tumor. The most common hematological malignancy was myelodysplastic neoplasms and the most common solid tumors included lung, skin, breast, colon and prostate cancers.</p> Conclusion <p>The findings suggest a gradual shift in CLL treatment patterns in Greece, with targeted agents increasingly replacing traditional chemoimmunotherapy in recent years and showing favorable survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Epameinondas Koumpis,
  • Eva Minga,
  • Persefoni Talimtzi,
  • Maria Angelopoulou,
  • Sofia Chatzileontiadou,
  • Maria Dimou,
  • Sotiria Besikli-Dimou,
  • Maria Efstathopoulou,
  • Dimitris Gogos,
  • Evdoxia Hatjiharissi,
  • Eleftheria Hatzimichael,
  • Michail Iskas,
  • Eliana Konstantinou,
  • Ioannis Kotsianidis,
  • Alexandros Machairas,
  • Eugenia Mpalaoura,
  • Anastasia Mpanti,
  • Panagiotis Panagiotidis,
  • Gerasimos Pangalis,
  • Ioannis Papadopoulos,
  • Maria Papaioannou,
  • Marina Siakantaris,
  • Niki Stavroyianni,
  • Theodoros Vassilakopoulos,
  • George Vrachiolias,
  • Kostas Stamatopoulos,
  • Anastasia Chatzidimitriou,
  • Thomas Chatzikonstantinou

摘要

Purpose

This study aims to characterize treatment patterns for chronic lymphocytic leukemia (CLL) in real-world clinical practice across Greece focusing on both treatment-naïve and relapsed or refractory (R/R) disease. We evaluated therapeutic patterns and outcomes [including overall survival (OS), time to next treatment or death (TTNT-D) and overall response rate (ORR)] and documented the incidence of other malignancies of patients who initiated first-line treatment between 2010 and 2024.

Methods

This is a panhellenic multicenter retrospective study of patients diagnosed with CLL between 2010 and 2020 from 8 centers in Greece.

Results

Overall, 1318 patients were included in the study. Fludarabine, cyclophosphamide and rituximab (FCR) was the most common first-line regimen (21.6%), followed by chlorambucil plus rituximab (16.3%) and ibrutinib-based therapies (14%). In the R/R setting, ibrutinib and venetoclax-based treatments, became the predominant therapeutic choices after 2014, replacing chemoimmunotherapy. Shifts in treatment patterns before and after 2016 reflected the incorporation of targeted agents into routine clinical practice, with a marked decline in FCR use and increased adoption of targeted therapies. Median OS was 162 months from diagnosis and 105.2 months (95% CI: 90.3–116.3) from first treatment. In patients receiving ibrutinib as first-line therapy, mOS was not reached, and median TTNT-D was 67.3 months.

Overall, 18 (1.4%) cases developed a second hematological malignancy and 59 (4.5%) were diagnosed with a solid tumor. The most common hematological malignancy was myelodysplastic neoplasms and the most common solid tumors included lung, skin, breast, colon and prostate cancers.

Conclusion

The findings suggest a gradual shift in CLL treatment patterns in Greece, with targeted agents increasingly replacing traditional chemoimmunotherapy in recent years and showing favorable survival outcomes.